AMPH · NASDAQ
Amphastar Pharmaceuticals (AMPH) Stock Price & Fundamentals
Amphastar Pharmaceuticals (AMPH) closed at $287.25 on Oct 9, 2026, up 0.58% from the previous close of $285.58.
Share price, past year
1Y +19.95%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $287.25 |
| Sep 30, 2026 | $293.37 |
| Aug 31, 2026 | $275.32 |
| Jul 31, 2026 | $270.52 |
| Jun 30, 2026 | $271.52 |
| May 29, 2026 | $286.85 |
| Apr 30, 2026 | $279.18 |
| Mar 31, 2026 | $254.26 |
| Feb 27, 2026 | $249.23 |
| Jan 30, 2026 | $224.29 |
| Dec 31, 2025 | $245.47 |
| Nov 28, 2025 | $237.65 |
| Oct 31, 2025 | $235.82 |
Key statistics
- Market cap
- $12.22B
- P/E (TTM)
- 170.0
- EPS (TTM)
- $1.69
- Revenue (TTM)
- $730.02M
- Net income (TTM)
- $78.55M
- Shares outstanding
- 42.5M
- Dividend yield
- —
- 52-week range
- $219.85 – $293.93
Amphastar Pharmaceuticals's market cap is $12.22B, based on a share price of $287.25 and 42.5M shares outstanding as of Jun 30, 2026.
Financials
Amphastar Pharmaceuticals reported revenue of $719.89M for fiscal 2025, down 1.65% from fiscal 2024.
Amphastar Pharmaceuticals earned net income of $98.09M in fiscal 2025, a net margin of 13.6%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $719.89M | −1.7% | $98.09M | 13.6% | $2.03 | $121.23M |
| FY2024ended Dec 31, 2024 | $731.97M | +13.6% | $159.52M | 21.8% | $3.06 | $172.35M |
| FY2023ended Dec 31, 2023 | $644.40M | +29.1% | $137.55M | 21.3% | $2.60 | $145.34M |
| FY2022ended Dec 31, 2022 | $498.99M | +14.0% | $91.39M | 18.3% | $1.74 | $65.15M |
| FY2021ended Dec 31, 2021 | $437.77M | +25.1% | $62.12M | 14.2% | $1.25 | $70.54M |
| FY2020ended Dec 31, 2020 | $349.85M | +8.5% | $1.40M | 0.4% | $0.03 | $23.41M |
| FY2019ended Dec 31, 2019 | $322.36M | +9.4% | $48.94M | 15.2% | $0.98 | $207.00K |
| FY2018ended Dec 31, 2018 | $294.67M | +22.7% | −$5.74M | −2.0% | −$0.12 | −$8.62M |
| FY2017ended Dec 31, 2017 | $240.18M | −5.9% | $3.65M | 1.5% | $0.08 | $4.11M |
| FY2016ended Dec 31, 2016 | $255.17M | — | $9.82M | 3.9% | $0.21 | $17.18M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $183.90M | $30.35M | $0.67 |
| Q1 FY2026ended Mar 31, 2026 | $171.17M | $6.42M | $0.14 |
| Q4 FY2025ended Dec 31, 2025 | $183.11M | $24.43M | $0.51 |
| Q3 FY2025ended Sep 30, 2025 | $191.84M | $17.35M | $0.37 |
| Q2 FY2025ended Jun 30, 2025 | $174.41M | $31.03M | $0.64 |
| Q1 FY2025ended Mar 31, 2025 | $170.53M | $25.29M | $0.51 |
| Q4 FY2024ended Dec 31, 2024 | $186.52M | $37.96M | $0.74 |
| Q3 FY2024ended Sep 30, 2024 | $191.21M | $40.43M | $0.78 |
Company profile
- Name
- Amphastar Pharmaceuticals, Inc.
- Ticker
- AMPH
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 11570 Sixth Street, Rancho Cucamonga, CA 91730
- Fiscal year ends
- December
- SEC CIK
- 0001297184
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jul 13, 2026
- Jul 8, 2026
- Jun 3, 2026
- May 7, 2026
- May 7, 2026
- Mar 16, 2026
Frequently asked questions
What is Amphastar Pharmaceuticals's stock price?
Amphastar Pharmaceuticals (AMPH) closed at $287.25 on Oct 9, 2026, up 0.58% from the previous close of $285.58.
What is Amphastar Pharmaceuticals's market cap?
Amphastar Pharmaceuticals's market cap is $12.22B, based on a share price of $287.25 and 42.5M shares outstanding as of Jun 30, 2026.
How much revenue does Amphastar Pharmaceuticals make?
Amphastar Pharmaceuticals reported revenue of $719.89M for fiscal 2025, down 1.65% from fiscal 2024.
What is AMPH's P/E ratio?
Amphastar Pharmaceuticals's price-to-earnings ratio is 170.0, based on trailing twelve-month diluted EPS of $1.69.
Does Amphastar Pharmaceuticals pay a dividend?
Amphastar Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Amphastar Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures